Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107770 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)
A Phase 1 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00107770 is a Phase 1 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 40 participants.
The verdict
NCT00107770, a Phase 1 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety of sodium phenylbutyrate (NaPB) treatment in subjects with amyotrophic lateral sclerosis (ALS) and the ability to take this medication without major side effects.
Interventions
- DRUG sodium phenylbutyrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107770
The ClinicalTrials.gov registry entry for NCT00107770 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sodium phenylbutyrate is the first listed.
NCT00107770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00107770 about?
NCT00107770 is a clinical study titled "Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)". The purpose of the study is to evaluate the safety of sodium phenylbutyrate (NaPB) treatment in subjects with amyotrophic lateral sclerosis (ALS) and the ability to take this medication without major side effects.
What is the current status of trial NCT00107770?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2005-04. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00107770?
The interventions under investigation include: sodium phenylbutyrate (DRUG).
Who is sponsoring clinical trial NCT00107770?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.